Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MEI Pharma, Inc.

< Previous 1 2 Next >
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Responds to Anson and Cable Car
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Board of Directors Rejects Unsolicited Proposal
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces 1-for-20 Reverse Stock Split
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
From MEI Pharma, Inc.
Via Business Wire
Tickers INFI MEIP
MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Initiates Strategic Realignment
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Changes to Board of Directors
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
From MEI Pharma, Inc.
Via Business Wire
Tickers MEIP
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.